Eight Weeks of Glecaprevir-Pibrentasvir Is Effective for Chronic HCV Genotype 1 or 3 Infection

Glecaprevir (an NS3/4A protease inhibitor) combined with pibrentasvir (an NS5A inhibitor) is the latest FDA-approved treatment regimen for hepatitis C virus (HCV) infection. In two industry-funded, phase III, open-label trials, researchers tested the safety and efficacy of glecaprevir/pibrentasvir in patients without cirrhosis who had HCV genotype 1 or 3 infection.

Over 700 patients with genotype 1 infection (including 33 co-infected with HIV) were randomized in a 1:1 ratio to receive glecaprevir/pibrentasvir for either 8 or 12 weeks, and over 500 treatment-naive patients with genotype 3 infection were randomized in a 2:1 ratio to receive glecaprevir/pibrentasvir or sofosbuvir/daclatasvir for 12 weeks. Another 150 patients with genotype 3 in…